MA-CONFORMATION-X-THER
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Outpost24 Acquires Infinipoint to Power Its Entry into the Zero Trust Workforce Access Market9.12.2025 08:00:00 CET | Press release
The strategic acquisition strengthens market leadership by unifying user identity with device trust, eliminating security blind spots. Outpost24, a leader in exposure management and identity security, today announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks Outpost24’s entry into the Zero Trust Workforce Access market and enhances its identity security division, Specops, by laying the foundation for a unified approach that evaluates both the user and the device before access is granted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208750630/en/ Ido Erlichman, Chief Executive Officer of Outpost24. As organizations advance their Zero Trust strategies, authentication alone is no longer enough. MFA and SSO confirm who the user is, but they do not validate the security of the device being used. In hybrid environments where employee
VSO Submits VCP v1.0 to Nineteen Regulatory Authorities Across Thirteen Jurisdictions and Completes First Integrated Evaluation in a Production-Like Environment9.12.2025 08:00:00 CET | Press release
The VeritasChain Standards Organization (VSO) announced today that it has submitted the VeritasChain Protocol (VCP) v1.0 to nineteen regulatory authorities across thirteen jurisdictions, including the United States, United Kingdom, European Union, Singapore, Hong Kong, United Arab Emirates (DIFC), Australia, India, South Korea, Switzerland, Brazil, Liechtenstein, and Saudi Arabia. The submissions present VCP v1.0 as a cryptographic audit framework designed to address emerging supervisory requirements under the EU AI Act Article 12 for logging and traceability, and MiFID II / RTS 25 for timestamp integrity and event ordering in AI-driven and algorithmic trading systems. VSO also confirmed the first completed integration of VCP v1.0 within a controlled, production-like evaluation environment operating under its Early Access Program. The environment successfully generated cryptographically linked event chains, immutable hashing, and verifiable proofs using RFC-aligned structures, demonstr
ENGIE and NHOA Energy Expand Their Partnership in Belgium to Build a New 320 MWh Battery Energy Storage System9.12.2025 08:00:00 CET | Press release
The project strengthens the strategic partnership with ENGIE and reinforces NHOA Energy’s long-term commitment to the Benelux markets NHOA Energy, global provider of utility-scale energy storage systems, has been awarded by ENGIE the contracts for the Supply, Commissioning and the Long-Term Service of a new 80 MW / 320 MWh Battery Energy Storage System (BESS) to be installed at the site of ENGIE’s Drogenbos power station, near Brussels. The Drogenbos BESS represents ENGIE’s third large-scale battery asset in Belgium and was selected in the country’s fifth Capacity Remuneration Mechanism (CRM) auction, securing a 15-year contract starting in November 2027. Designed to deliver essential flexibility services to the Belgian grid, enabling greater integration of renewable energy and supporting grid stability at national level, the BESS will be based on NHOA Energy’s NHEXUS platform, including 88 battery containers capable of providing up to 4 hours of discharge, corresponding to the average
2025 Sees Double-digit Increase in Tourists' Spending via Alipay+ in South Korea as Travellers Seek More Local Experiences9.12.2025 07:55:00 CET | Press release
- Total number of Alipay+ QR code payment transactions in South Korea increased 18%, with total payment volume (TPV) growing 16% year-on-year - Beauty clinic, transportation and F&B are some of the fastest-growing categories in spending with Alipay+ Alipay+, Ant International’s global wallet gateway services, revealed an 18% increase in Alipay+-supported QR code payment transactions, with total payment volume (TPV) growing 16% year-on-year in South Korea, as more tourists use Alipay+ partner wallets and bank apps to make digital payments for a range of services, from beauty clinic treatments and transportation to night market food stalls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208351936/en/ Weixiao Jiang, General Manager North Asia and North America, Alipay+, Ant International South Korea is among the top destinations for tourists from regions such as Southeast Asia and the Chinese mainland, with the greatest numb
Interactive Brokers Expands Market Access with United Arab Emirates Equities9.12.2025 07:00:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the introduction of United Arab Emirates (UAE) equities through two leading exchanges in one of the world’s fastest-growing economic regions. Clients of Interactive Brokers worldwide can now access the Abu Dhabi Securities Exchange (ADX) and the Dubai Financial Market (DFM). This enables investors in the region to trade both local and international markets from a single platform while investors worldwide can build diversified portfolios across asset classes and geographies, including countries in the growing Gulf Cooperation Council (GCC). Interactive Brokers serves a global client base and is uniquely equipped to advance the financial goals of individual and institutional investors worldwide, including those in the Middle East. Adding UAE stocks further expands Interactive Brokers’ market access and enhances the investment opportunities available to local and global investors. Interactive Broker
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom